Preliminary 2025 results from Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. furnished a current report to share that it issued a press release with certain business updates and preliminary financial information for the year and fiscal quarter ended December 31, 2025. The disclosure was made in connection with the 44th Annual J.P. Morgan Healthcare Conference, highlighting recent operational and financial developments.

The press release is included as Exhibit 99.1 to the report and is incorporated by reference. The company specifies that this information is being furnished under Item 2.02, rather than filed, which limits how it is treated under securities law unless another filing specifically incorporates it by reference.

false000087330300008733032026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Sarepta Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-14895	93-0797222
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
215 First Street
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 274-4000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SRPT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, Sarepta Therapeutics Inc. issued a press release disclosing certain business updates, including preliminary financial information as of and for the year and fiscal quarter ended December 31, 2025, in connection with the 44th Annual J.P. Morgan Healthcare Conference. A copy of the press release is furnished with this report as Exhibit 99.1 and incorporated by reference herein.

The information in this report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated January 12, 2026
104	The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Sarepta Therapeutics, Inc.
Date:	January 12, 2026	By:	/s/ Douglas S. Ingram
			Douglas S. Ingram Chief Executive Officer

FAQ

What did Sarepta Therapeutics (SRPT) disclose in this 8-K?

Sarepta Therapeutics reported that it issued a press release providing certain business updates and preliminary financial information for the year and quarter ended December 31, 2025.

Which period does Sarepta Therapeutics’ preliminary financial information cover?

The preliminary financial information covers the full fiscal year and fiscal quarter ended December 31, 2025.

Where can investors find the detailed updates Sarepta provided?

The detailed business updates and preliminary financial information are contained in the press release furnished as Exhibit 99.1 to the report.

How is the information in Sarepta’s press release treated under securities laws?

The company states that the information, including Exhibit 99.1, is furnished under Item 2.02, not deemed filed or subject to Section 18 liabilities unless another filing specifically incorporates it by reference.

Why did Sarepta issue this update in connection with the J.P. Morgan Healthcare Conference?

The company notes that the press release with business updates and preliminary financial information was issued in connection with the 44th Annual J.P. Morgan Healthcare Conference.

Which exhibit in the 8-K contains Sarepta’s January 12, 2026 press release?

The press release dated January 12, 2026 is included as Exhibit 99.1 to the report.